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Abstract
Background: Recent data from this laboratory suggest that components of dairy foods may serve as activators of
SIRT1 (Silent Information Regulator Transcript 1), and thereby participate in regulation of glucose and lipid
metabolism. In this study, an ex-vivo/in-vitro approach was used to examine the integrated effects of dairy diets on
SIRT1 activation in two key target tissues (adipose and muscle tissue).
Methods: Serum from overweight and obese subjects fed low or high dairy diets for 28 days was added to
culture medium (similar to conditioned media) to treat cultured adipocytes and muscle cells for 48 hours.
Results: Treatment with high dairy group conditioned media resulted in 40% increased SIRT1 gene expression in
both tissues (p < 0.01) and 13% increased enzyme activity in adipose tissue compared to baseline. This was
associated with increased gene expression of peroxisome proliferator-activated receptor-gamma coactivator 1 alpha
(PGC-1a), nuclear respiratory factor 1 (NRF1), cytochrome oxidase c subunit 7 (Cox 7), NADH dehydrogenase and
uncoupling protein 2 (UCP2) in adipocytes as well as uncoupling protein 3 (UCP3), NRF1 and Cox 7 in muscle cells
(p < 0.05). Further, direct incubation of physiological concentrations of leucine and its metabolites a-Ketoisocaproic
acid (KIC) and b-hydroxy-methylbuteric acid (HMB) with recombinant human SIRT1 enzyme resulted in 30 to 50%
increase of SIRT1 activity (p < 0.05).
Conclusions: These data indicate that dairy consumption leads to systemic effects, which may promote
mitochondrial biogenesis in key target tissues such as muscle and adipose tissue both by direct activation of SIRT1
as well as by SIRT1-independent pathways.
Keywords: SIRT1, Dairy, Leucine, b?β?-Hydroxy-b?β?-Methylbutyrate (HMB), a?α?-ketoisocaproate (KIC), Adipose tis-
sue, Muscle, Insulin sensitivity, Mitochondrial biogenesis
Background
The beneficial effects of energy restriction on lifespan
and protection against metabolic disease are mediated,
in part, by SIRT1 (Silent Information Regulator Tran-
script 1) and SIRT3 in mammals and by the SIRT1
orthologue Sir2 in lower species [1]. Both SIRT1 and
SIRT3 are NAD
+-dependent class III protein deacety-
lases which sense the energy/nutrient status via the
NAD
+/NADH ratio [2]. While SIRT3 is mainly located
in the mitochondria, SIRT1 functions as a transcrip-
tional repressor via histone deacetylation in the nucleus.
However, it also modifies the acetylation level of
transcription factors such as p53, NF-Ba n dF O X O
[1,3]. Activation of SIRT1 stimulates PGC1a,w i t hc o n -
sequent activation of mitochondrial biogenesis and
metabolism [4] and associated improvements of insulin
sensitivity and suppression of oxidative and inflamma-
tory stress [5,6].
Dairy foods have been reported to have multiple
effects on adipocyte and muscle metabolism and there-
fore play a significant role in modulating energy meta-
bolism and obesity risk [7-9]. While some of these
effects appear to be mediated by dietary calcium [10],
recent evidence indicates that the high concentration of
branched chain amino acids (BCAA) contribute to these
effects. In particular, the BCAA leucine plays a distinct * Correspondence: mzemel@utk.edu
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naling and as it appears to play an important role in the
re-partitioning of dietary energy from adipose to skeletal
muscle [11], although it is not clear whether these
effects are mediated by intact leucine or by its’ metabo-
lites a-ketoisocaproate (KIC) and b-Hydroxy-b-Methyl-
butyrate (HMB).
Our recent data indicate that components of dairy
foods may serve as activators of SIRT1. Leucine admin-
istration stimulated mitochondrial biogenesis and fat
metabolism in both adipocytes and muscle cells; these
effects were mediated, in part, by SIRT1, and SIRT1
knockdown markedly attenuated the effects [12]. In con-
trast calcitriol, which is increased in response to subop-
timal calcium intake, inhibited mitochondrial biogenesis,
increased energy efficiency and reactive oxygen species
(ROS) generation [12,13]. In addition, data from our
mouse microarray study suggest that dairy components,
especially calcium and leucine, up-regulate SIRT1-
dependent signaling pathways for fat oxidation, attenu-
ate pathways of inflammatory response (including NF-
B signaling) and stimulate insulin signaling in skeletal
muscle and adipose tissue [14]. Furthermore, consistent
with reports of SIRT1 effects on lifespan, dairy-rich
diets reduced the early mortality in mice [15].
These observations provided the mechanistic frame-
work for our hypothesis that calcitriol and leucine modu-
lation of SIRT1 in adipose tissue and skeletal muscle is
the central signaling event that links the effects of calci-
triol, leucine and dairy foods on fatty acid oxidation, oxi-
dative stress, insulin sensitivity and inflammatory stress.
Since adiposity is associated with changes in glucose and
lipid metabolism, we tested this hypothesis in overweight
and obese subjects using an ex-vivo/in-vitro approach in
which subjects were fed low or high dairy diets to provide
serum to utilize in cell studies. The serum reflected the
integrated systemic response to the diets and was then
added to culture medium (analogous to conditioned
medium) to treat cultured human adipocytes and muscle
cells, separately and in co-culture, in order to assess the
integrated effects of dairy feeding on SIRT1 activation in
these two key target tissues (Figure 1).
Materials and methods
Clinical intervention (in-vivo study)
Subjects
Twenty otherwise healthy adults [14 males, 6 females;
10 overweight (BMI 25.0 - 29.9) and 10 mildly obese
(Stage 1 obesity; BMI 30.0-34.9)] were recruited from
the faculty, staff and student populations of the Univer-
sity of Tennessee. Enrolled subjects were 31.0 ± 10.3
years of age. Subjects were excluded for the following
reasons: BMI <25 or ≥ 30 (overweight subjects) or < 30
or ≥ 35 (obese subjects); type II diabetes requiring the
use of any oral antidiabetic agent and/or insulin; his-
tory/presence of significant metabolic disease, active gas-
trointestinal disorders, or eating disorders; adverse
response to dairy foods; recent use of tobacco, pharma-
cotherapeutic agents, over-the-counter anti-obesity
agents, or psychotropic medication; recent initiation of
an exercise program, recent initiation/change in hormo-
nal birth control or hormone replacement therapy, or
pregnancy/lactation.
Interventions
Two weight-maintenance diets (soy-based placebo diet
(500-600 mg calcium/day) and a dairy diet (three daily
servings; 1200-1400 mg calcium/day) were presented to
the subject groups in a randomized crossover design.
Each diet was presented for 28 days, with fasted plasma
obtained at baseline (day 0), day 7 and day 28 of each
dietary period. Diets were presented in random order.
Half of the overweight and half of the obese subjects
received the dairy-free diet first and the other half
received the dairy-adequate diet first. The two dietary
periods were separated by a 28-day washout period.
After washout, the study was repeated with subjects
exposed to the other diet for an additional 28 days.
Dietary intervention in females commenced during the
luteal stage (14-24 days) after the onset of menses to
control for confounding of menstrual cycle and oxida-
tive and/or inflammatory stress; this resulted in a longer
>28-day washout for some subjects (up to 38 days) in
order to start at the same point in the menstrual cycle
for both phases of the cross-over. This study was
approved from an ethical standpoint by the Institutional
Review Board of the University of Tennessee-Knoxville
and written informed consent was obtained from the
participants of this study. This study was registered at
clinicaltrials.gov (NCT00686426). The primary purpose
of this study was to assess the effects of dairy versus soy
on oxidative and inflammatory stress, and the results on
those outcomes were recently reported [16]
Diets
Two diets (dairy and soy) in the form of “smoothies”
were administered three times per day throughout each
28-day treatment period. Each smoothie contained 170
kcal, 10 grams protein, 1 gram fat and 30 grams carbo-
hydrate. Two of the daily smoothies were consumed by
s u b j e c t sa tt h ec l i n i cs i t ea n dt h et h i r dw a st a k e nf o r
off-site consumption. The dairy smoothies were milk-
based, using non-fat dry milk as the protein source, and
contained 350 mg calcium per smoothie. The placebo
smoothies used soy protein isolate as the protein source
and contained 50 mg calcium per smoothie. For both
dairy and placebo, subjects were provided a choice of
fruit flavorings. The two diets (smoothies plus other
foods consumed) were constructed to provide compar-
able levels of macronutrient and fiber–approximating
Bruckbauer and Zemel Nutrition & Metabolism 2011, 8:91
http://www.nutritionandmetabolism.com/content/8/1/91
Page 2 of 12the average consumption in the U.S. (fat, ~35% of total
kcal, carbohydrates ~49%, protein ~16%, fiber 8-12 g/
day). Maintenance levels of calorie intake were deter-
mined from measurement of resting metabolic rate
(RMR) via indirect calorimetry. Total daily energy
expenditure and maintenance energy requirements were
calculated as 1.2 - 1.4 X RMR, depending upon level of
physical activity.
Nutritional supplements were not permitted. Caffeine
intake was maintained at a constant level per subject
based on baseline assessment. Subjects were given indi-
vidual instruction, counseling and assessment from the
study dietitian regarding dietary adherence. All subjects
maintained complete diet and physical activity diaries
throughout the study.
In-vitro Study
Serum of day 0, 7 and 28 of each of the two dietary per-
iods (dairy and soy) from six individual subjects was uti-
lized. This provided a baseline for each dietary period
and short- (7 day) and intermediate-term (28 day)
assessment of the effects of diet on SIRT1. Serum was
diluted with the adipocyte or myocyte culture media at
25% vol/vol and cells were incubated for 48 hours at 37°
C. For each subject, gene expression analysis was per-
formed in two cell replicates and SIRT1 activity in three
cell replicates.
Cell Culture
Human Adipocytes
Human omental cultured adipocytes were obtained as
plated differentiated adipocytes at 2 weeks old from
Zen-Bio, Inc. (Research Triangle, NC, USA), originally
isolated from the omental visceral fat depot from four
healthy obese female subjects (average age 40 y old,
average BMI = 45.6 kg/m
2). Cells were handled accord-
ing to manufacture’s instructions. Prior to each experi-
ment, cells were transferred to a low serum medium
(0.2% fetal bovine serum (FBS)) overnight. Cells were
then washed with fresh serum-free medium and re-fed
Figure 1 The ex-vivo/in-vitro Approach. 20 overweight or obese subjects were fed a low (soy) or high dairy diet for 28 days in a cross-over
design. Blood from each intervention period was drawn at start (day 0), at day 7 and at the end (day 28) to provide serum to utilize in cell
studies. The serum reflected the integrated systemic response to the diets and was then added to culture medium (as serum conditioned
medium) to treat cultured human adipocytes and muscle cells, separately and in co-culture, for 48 hours in order to assess the integrated effects
of dairy feeding on SIRT1 activation in two key target tissues.
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cated serum treatments and incubated at 37°C in 5%
CO2 f o r4 8h o u r sp r i o rt oa n a l y s i s( S I R T 1a c t i v i t yo r
RNA extraction for gene expression). Cell viability was
measured by trypan blue exclusion.
Mouse adipocytes
3T3-L1 preadipocytes were incubated at a density of
8000 cells/cm2 (10 cm2 dish) and grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FBS
and antibiotics (1% penicillin/streptomycin) at 37°C in
5% CO2 in air. Confluent preadipocytes were induced to
differentiate with a standard differentiation medium
consisting of DMEM-F10 (1:1, v/v) medium supplemen-
ted with 10% FBS, 1 μM dexamethasone, 0.5 mM isobu-
tylmethylxanthine, and antibiotics (1% penicillin/
streptomycin). Preadipocytes were maintained in this
differentiation medium for 3 days and subsequently cul-
tured in adipocyte medium. Cultures were re-fed every
2 to 3 days to allow 90% cells to reach full differentia-
tion. Before treatment cells were incubated in low
s e r u mm e d i u m( 0 . 2 % F B S )o v e r n i g h ta n dt h e nw a s h e d
with fresh medium, re-fed with medium containing the
different serum treatments and incubated at 37°C in 5%
CO2 for 48 h before analysis.
Mouse myocytes
C2C12 cells were incubated at a density of 8000 cells/
cm2 (10 cm2 dish) and grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% FBS and anti-
biotics (1% penicillin/streptomycin) at 37°C in 5% CO2
in air. Cells were grown to 100% confluence, changed
into differentiation medium (DMEM with 2% horse
serum and 1% penicillin/streptomycin), and fed with
fresh differentiation medium every other day until myo-
tubes were fully formed (6 days). Cells were then used
for co-culture as described below.
Adipocyte-myocyte co-culture
Cells are co-cultured using transwell inserts with a 0.4
μm porous membrane (Corning) to separate adipocytes
and muscle cells, as previously described [11,12,17].
Each cell type was grown independently in transwell
plates and, following differentiation, inserts containing
adipocytes are transferred to myotubes plates. The cells
are then incubated in DMEM-medium with antibiotics
containing the indicated serum treatments and incu-
bated at 37°C in 5% CO2 for 48 hours, after which cells
in the lower well are harvested for further analysis.
RNA extraction
The Ambion ToTALLY RNA isolation kit (Ambion, Inc.,
Austin, Tex., USA) was used to extract total RNA from
cells according to the manufacturer’s instruction. The con-
centration, purity and quality of the isolated RNA were
assessed by measuring the 260/280 ratio (1.8-2.0) and 260/
230 ratio (close to 2.0) by using the ND-1000 Spectrophot-
ometer (NanoDrop Technologies Inc., Del. USA).
Gene Expression
Expression of adipocyte and myocyte 18S, SIRT1,
PGC1-a, cytochrome c oxidase subunit VIIc1 (Cox 7c),
mitochondrial NADH dehydrogenase (MT-ND1 and
NDUFA), nuclear respiratory factor 1 (NRF1) and
uncoupling protein (UCP2 (adipocyte)/UCP3 (myocyte)
was measured via quantitative real-time PCR using an
ABI 7300 Real-Time PCR system (Applied Biosystems,
Branchburg, NJ) with a TaqMan
® core reagent kit. All
primers and probe sets were obtained from Applied Bio-
systems TaqMan
® Assays-on-Demand and utilized
accordingly to manufacturers instructions. Pooled RNA
from each cell type was serial-diluted in the range of
0.0156 - 50 ng and used to establish a standard curve;
total RNA for each unknown sample was also diluted in
this range. RT-PCR reactions were performed according
to the instructions of the ABI Real-Time PCR system
and TaqMan Real Time PCR Core Kit. Expression of
each gene of interest was then normalized using the cor-
responding 18S quantitation. Data for each gene is pre-
sented as a ratio to 18S.
SIRT1 Activity
SIRT1 activity was measured by using the SIRT1 Fluori-
metric Drug Discovery Kit (BML-AK555, ENZO Life
Sciences International, Inc. PA, USA). In this assay,
SIRT1 activity is assessed by the degree of deacetylation
of a standardized substrate containing an acetylated
lysine side chain. The substrate utilized is a peptide con-
taining amino acids 379-382 of human p53 (Arg-His-
Lys-Lys[Ac]), an established target of SIRT1 activity;
SIRT1 activity is directly proportional to the degree of
deacetylation of Lys-382. For activator screening of
SIRT1, 0.5 mM Leucine, 0.5 mM KIC or 0.05 mM
HMB were added to human recombinant SIRT1 enzyme
and incubated with peptide substrate (25 μM), and
NAD
+ (500 μM) in a phosphate-buffered saline solution
at 37°C on a horizontal shaker for 45 minutes. The reac-
tion was stopped with the addition of 2 mM nicotina-
mide and a developing solution that binds to the
deacetylated lysine to form a fluorophore. Following 10
minutes incubation at 37°C, fluorescence was read in a
plate-reading fluorometer at an excitation wavelength of
360 nm and an emission wavelength of 450 nm. For
endogenous SIRT1 activation, the assay was modified by
using 2.5 ul of adipose or muscle cell lysate. In each
assay, human recombinant SIRT1 enzyme (1 Unit per
well), resveratrol (20 mM for cell lysate assays, and 10
and 2 mM for activator screening), a SIRT1 activator,
and suramin sodium (5 mM), a SIRT1 inhibitor were
utilized as positive and negative controls in each set of
reactions. A standard curve was constructed using deac-
tylated substrate (0-10 μM). Data for endogenous SIRT1
activation were normalized to cellular protein concen-
tration measured via BCA-assay.
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Change from baseline values were computed for each
outcome variable. All data were then expressed as mean
percent change from baseline ± SE. Data were analyzed
by one-way ANOVA, and significantly different group
means (p < 0.05) were then separated by the least signif-
icant difference test using SPSS (SPSS Inc, Chicago, IL).
Results
Treatment of cultured adipocytes and myocytes with
serum obtained from subjects fed a high dairy diet for 4
weeks resulted in significant changes of SIRT1 activity
and gene expression as well of mitochondrial compo-
nent genes. Figure 2 shows that incubation of human
adipocytes with serum drawn after 28 days of high dairy
treatment increased significantly both SIRT1 activity
(Figure 2a) and SIRT1 gene expression (Figure 2b) by
13 and 40%, respectively, compared to baseline while
the soy-based diet had no significant effect. These
effects were associated with concomitant changes in
mitochondrial biogenesis indicated by increased gene
expression of uncoupling protein (UCP)-2 (Figure 3a)
and PGC-1a (Figure 3b) by 20 and 90% (p < 0.05),
respectively. In addition, mitochondrial component
genes such as mitochondrial NADH dehydrogenase (Fig-
ure 4c and d), cytochrome C oxidase (Cox 7c) (Figure
4a) and nuclear respiratory factor (NRF-1) (Figure 4b)
were highly up-regulated by dairy. Similar effects could
be noted after treatment of mouse 3T3-L1 adipocytes
with the human serum (data not shown).
Next, we treated C2C12 muscle cells in co-culture
with 3T3-L1-adipocytes with serum obtained from the
subjects after dairy or soy feeding. Dairy feeding resulted
in 43% increase of SIRT1 gene expression in the muscle
cells (p < 0.05), which was significantly different from
baseline and soy-based control (Figure 5b). Although
there was no difference detected for SIRT1 activity (Fig-
ure 5a), genes such as Cox-7c, nuclear respiratory factor
(NRF)-1 and UCP3 were significantly up-regulated by
22%, 29% and 32% (p < 0.05), respectively, by treatment
with serum from 28 days after dairy feeding suggesting
that mitochondrial biogenesis was also stimulated in
muscle cells (Figure 6, ba, and 6c).
To test, whether Leucine and its metabolites b-
Hydroxy-b-Methylbutyrate (HMB) and Ketoisocaproate
(KIC) are direct activators of SIRT1, we incubated these
Figure 2 The effects of serum treatment on SIRT1 activity (a) and SIRT1 gene expression (b) in human adipocytes. Cultured human
adipocytes were incubated for 48 hours with human serum collected on day 0 (baseline), 7 or 28 after high dairy diet or soy-based control diet.
Values are expressed as means of % change to baseline ± SE (n = 5 subjects/group). Differing letters above the bars denote significant
differences between groups, p ≤ 0.05.
Bruckbauer and Zemel Nutrition & Metabolism 2011, 8:91
http://www.nutritionandmetabolism.com/content/8/1/91
Page 5 of 12compounds with recombinant human SIRT1 enzyme
and measured the activity of SIRT1 by the amount of
deacetylated substrate. All three compounds were able
to directly increase SIRT1 activity by 30 to 100%, which
was comparable to the effects of low dose (2 to 10 μM)
resveratrol while valine, used as a branched-chain amino
acid control, had no effect (Figure 7).
Discussion
This ex-vivo/in-vitro study indicates that high dairy feed-
ing in humans over 4 weeks results in significant sys-
temic changes which may induce activation of SIRT1
and downstream targets of mitochondrial biogenesis in
key target tissues as demonstrated here in muscle and
adipose cells. These effects may contribute to observed
changes in energy metabolism and oxidative and inflam-
matory stress. We previously reported that the high
d a i r yi n t a k ei nt h i sc l i n i c a ls t u d yr e s u l t e di ns i g n i f i c a n t
suppression of oxidative and inflammatory biomarkers,
including reductions in plasma malondialdehyde, 8-iso-
prostane-F2,T N F - a, IL-6 and MCP-1, and increased
levels of the anti-inflammatory cytokine adiponectin
[16]. We have also shown that dairy components,
especially calcium and leucine, up-regulated signaling
pathways for fat oxidation, attenuated inflammatory
pathways such as NF-B signaling and stimulated insu-
lin signaling in skeletal muscle and adipose tissue, sug-
gesting a SIRT1 dependent regulation [14]. Similarly,
supplemental leucine intake by addition to drinking
water in mice rescued metabolic changes to a high fat
diet and was associated with improvement of glucose
tolerance and insulin signaling as well as decrease in
adipose tissue inflammation [18]. Although the authors
of this study did not assess SIRT1 activation, SIRT1
dependence is consistent with their observations. Yoshi-
zaki et al [6] reported beneficial effects of SIRT1 activa-
tion on glucose uptake and insulin signaling, and
improvement of inflammatory markers in 3T3-L1 adipo-
cytes while SIRT1 depletion exerted the opposite effect.
Moreover, modest global overexpression of SIRT1 in
mice resulted in protection against metabolic damage
from a high-fat diet by up-regulation of antioxidant pro-
teins such as MnSOD and NRF1, and lower lipid-
induced activation of pro-inflammatory cytokines such
as TNFa and IL-6 via reduction of NF-B [19]. These
effects were manifested in lower inflammation, improved
Figure 3 Effects of serum treatment on mitochondrial biogenesis in human adipocytes. Cultured human adipocytes were incubated for 48
hours with human serum collected on day 0 (baseline), 7 or 28 after high dairy diet or soy-based control diet. (a) Uncoupling protein 2 (UCP2)
and (b) PGC-1a were significantly increased by dairy at day 7 compared to baseline and soy-based diet. Values are expressed as means of %
change to baseline ± SE (n = 4 to 5 subjects/group). Gene expression data are normalized to 18S. Differing letters above the bars denote
significant differences between groups, p ≤ 0.05.
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hepatic steatosis. In contrast, heterozygous SIRT1
knockout (SIRT1
+/-) mice developed severe hepatic stea-
tosis on high-fat diets, accompanied by lower energy
expenditure and increased inflammation [20]. Accord-
ingly, our observation of increased SIRT1 activity and
expression in muscle and adipose tissue following incu-
bation with serum from subjects fed a high dairy diet
likely represents the mechanism of the observed reduc-
tion of oxidative and inflammatory stress in these sub-
jects. However, the present data are limited by the
opportunistic use of archival samples from our previous
clinical trial [16]; accordingly, no direct comparison of
the effects of increasing dairy food intake in lean vs.
obese subjects is possible.
Mitochondrial loss and/or dysfunction play a key role
in metabolic disorders such as insulin resistance, type II
diabetes and cardiovascular disease [21-23], and stimula-
tion of mitochondrial biogenesis with resveratrol
increased insulin sensitivity and prevented obesity and
insulin-resistance in mice fed a high-fat diet [24]. The
majority of mitochondrial proteins, including most of
those involved in oxidative phosphorylation, are nuclear
encoded and transported into the mitochondria from
the cytoplasm while only 13 protein subunits involved
in electron transport are encoded in the mitochondrial
genome (mtDNA) [2]. For mitochondrial biogenesis,
both the nuclear and mitochondrial protein subunits
have to form complexes and thus require a coordinated
crosstalk and regulation for proper function. PGC-1a,a
Figure 4 Effects of serum treatment on mitochondrial component genes in human adipocytes. Cultured human adipocytes were
incubated for 48 hours with human serum collected on day 0 (baseline), 7 or 28 after high dairy diet or soy-based control diet. (a) Cytochrome
c oxidase subunit 7 (Cox 7c), (b) nuclear respiratory factor 1 (NRF1), and mitochondrial NADH dehydrogenase ((c) mitochondrial encoded subunit
(MT-ND1) and (d) nuclear encoded subunit (NDUFA)) were significantly up-regulated after dairy feeding compared to baseline and soy diet.
Values are expressed as means of % change to baseline ± SE (n = 4 to 5 subjects/group). Gene expression data are normalized to 18S. Differing
letters above the bars denote significant differences between groups, p ≤ 0.05.
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chondrial biogenesis in response to external stimuli. Up-
regulation of PGC-1a activates the expression of
nuclear-encoded OxPhos components genes as well as
of nuclear respiratory factor (NRF1), which also regu-
lates the transcription of mitochondrial genes [25,26].
Although it is possible that the previously observed
systemic changes in oxidative and inflammatory biomar-
kers [16] may contribute to increased SIRT1 expression
and/or activity, we have previously demonstrated that
leucine administration stimulated mitochondrial biogen-
esis and metabolism in skeletal muscle and adipose cells
and that these effects were mediated, in part, by SIRT1
[12], while calcitriol treatment exerted the opposite
effects. Similarly, we demonstrate in this study that a
leucine rich diet in form of dairy results in up-regulation
of PGC-1a as well as in up-regulation of downstream
target genes such as NRF-1, UCP2 and 3, NADH dehy-
drogenase and cytochrome c oxidase indicative of stimu-
lated mitochondrial biogenesis in muscle and adipose
tissue. Although we cannot directly attribute the
observed ex vivo effects to the leucine content of the
high dairy diet, the concentrations of leucine used in
our in vitro studies are comparable to the plasma levels
typically achieved in response to leucine-rich milk or
whey-based diets [27], while soy protein isolate pro-
duced only ~30% the leucine level when studied at the
same protein load (10 g/dose).
Data from this study indicate that not only leucine but
also its metabolites HMB and KIC are direct activators
of SIRT1 enzyme. It has been suggested that some of
the leucine effects may be attributed to its metabolites,
which have also variable effects on protein metabolism
and immune function [28]. The majority of the first step
of leucine metabolism, the transamination to KIC,
occurs in muscle. Orally administered alpha-KIC to
food-deprived rats exerted stimulatory effects on pro-
tein-synthesis in skeletal muscle, similar to L-leucine
administration, but not in liver; however, it was not
clear whether these effects were direct effects of KIC or
caused by the reversible conversion of KIC to leucine
[29]. Earlier results demonstrated that incubation with
KIC could decrease protein degradation in rat dia-
phragms but did not stimulate protein synthesis while
leucine incubation did both [30].
Although effects of HMB supplementation on muscle
strength and gain are also conflicting, HMB has been
used as a therapeutical supplement for years to
Figure 5 The effects of serum treatment on SIRT1 activity (a) and SIRT1 gene expression (b) in mouse skeletal muscle. Cultured C2C12
muscle cells were grown in co-culture with 3T3-L1 adipocytes and incubated for 48 hours with human serum collected on day 0 (baseline), 7 or
28 after high dairy diet or soy-based control diet. Values are expressed as means of % change to baseline ± SE (n = 6 subjects/group). Differing
letters above the bars denote significant differences between groups, p ≤ 0.05.
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tions [31]. Some of this anti-catabolic activity seems to
be mediated by reduction of ROS formation [32]. In
addition, HMB may play a role as a potentially dietary
immunomodulator since it has been shown to decrease
proliferation and TNF-a production in stimulated
human peripheral blood monocytes by 35% [33] and
suppressed NF-B expression in tumor-bearing Wistar
rats, thereby reducing tumor growth and tumor cell pro-
liferation [34]. Since SIRT1 is a negative regulator of
NF-B [35,36] and attenuation of NF-kB activity by
SIRT1 results in suppression of TNF-a [37,38], it is pos-
sible that the above mentioned effects of HMB are
mediated, at least in part, by HMB activation of SIRT1.
It is not yet clear how leucine or its metabolites KIC
and HMB directly stimulate SIRT1 in a cell free system.
We speculate that they may act as allosteric activators
producing a conformational change in SIRT1, which
increases binding to its substrate.
The stimulation of mitochondrial biogenesis in muscle
cells was not associated with underlying changes in
SIRT1 activity, although SIRT1 gene expression was up-
regulated. Therefore, it is likely that SIRT1-independent
pathways also modulate some of the effects of dairy
components. AMP-activated protein kinase (AMPK), a
key regulator of energy metabolism, is a likely target, as
it also serves as an energy sensor and regulates cellular
metabolism. In addition, there is a bidirectional interac-
tion between AMPK and SIRT1; AMPK activates SIRT1
by increasing cellular NAD+ levels and, conversely,
SIRT1 stimulates AMPK by activation of LKB1 [39].
Since adiponectin activates AMPK [40], and we
Figure 6 Effects of serum treatment on mitochondrial biogenesis in mouse skeletal muscle cells. C2C12 muscle cells were grown in co-
culture with 3T3-L1 adipocytes and incubated for 48 hours with human serum collected on day 0 (baseline), 7 or 28 after high dairy diet or soy-
based control diet. (a) Cytochrome c oxidase subunit 7 (COX 7), (b) nuclear respiratory factor 1 (NRF1) and (c) UCP 3 were significantly up-
regulated 28 days after dairy feeding compared to baseline and soy-based control. Values are expressed as means of % change to baseline ± SE
(n = 6 subjects/group). Gene expression data are normalized to 18S. Differing letters above the bars denote significant differences between
groups, p ≤ 0.05.
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Page 9 of 12previously demonstrated the high dairy diet to increase
adiponectin (16), adiponectin stimulation of AMPK may
play a significant role in the observed effects.
Conclusions
In conclusion, we utilized an ex vivo/in-vitro approach
to test whether high dairy feeding in people is related to
underlying changes in key regulatory enzymes of meta-
bolism and mitochondrial biogenesis in muscle and adi-
pose tissue which may be responsible for observed
alterations in inflammatory and oxidative stress markers.
Our in-vitro results in muscle and adipose cells indicate
that systemic effects of dairy feeding may result in
SIRT1- activation in key target tissues such as muscle
and adipose tissue. This may represent one possible
central signaling event that links the effects of calcitriol,
leucine and dairy foods on fatty acid oxidation, oxidative
stress, insulin sensitivity and inflammatory stress.
Strengths of this study include the linkage of signaling
events in established cell systems to clinical dietary
interventions using a novel ex-vivo approach and the
control inherent in the randomized crossover design
clinical trial. Limitations of this study include those
inherent in extrapolating from ex-vivo to in-vivo,t h e
inability of this design to discriminate among the dairy
components responsible for the observed effects, and
the modest sample size limiting the degree to which
these findings may be generalized. In addition, we did
not examine the mechanism how leucine or its metabo-
lites directly stimulate SIRT1, and cannot exclude the
Figure 7 Direct effects of Leucine, b-Hydroxy-b-Methylbutyrate (HMB) and Ketoisocaproate (KIC) on SIRT1 activity. Recombinant human
SIRT1 enzyme was incubated with Leucine, HMB and KIC for 45 min and fluorescence of deacetylated substrate was measured. Resveratrol and
Suramin were used as positive and negative control, respectively. Valine was used as BCAA control. Data are expressed as means of % change of
SIRT1 activity ± SE (n = 4, p ≤ 0.05).
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Page 10 of 12possibility that binding to the fluorophore used in the
SIRT1 assay contributes to the observed increase in
SIRT1 activity.
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